This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
VOYA or SLF: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
VOYA vs. SLF: Which Stock Is the Better Value Option?
BBD vs. HDB: Which Stock Is the Better Value Option?
by Zacks Equity Research
BBD vs. HDB: Which Stock Is the Better Value Option?
GEF vs. PKG: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GEF vs. PKG: Which Stock Is the Better Value Option?
APELY vs. OLED: Which Stock Is the Better Value Option?
by Zacks Equity Research
APELY vs. OLED: Which Stock Is the Better Value Option?
OGN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OGN vs. DOCS: Which Stock Is the Better Value Option?
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
by Debanjana Dey
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
DOCS Boosts Client Retention via Workflow Integration and AI Tools
by Debanjana Dey
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
by Indrajit Bandyopadhyay
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
by Indrajit Bandyopadhyay
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
by Zacks Equity Research
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 40.74% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 0% and 7.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
by Zacks Equity Research
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 6.67% and 6.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Doximity (DOCS) concluded the recent trading session at $59.39, signifying a +0.1% move from its prior day's close.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DOCS: Which Stock Is the Better Value Option?
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Coya Therapeutics, Inc. (COYA) and Doximity (DOCS) have performed compared to their sector so far this year.
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day.
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
by Urmimala Biswas
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Enhabit (EHAB) and Doximity (DOCS) have performed compared to their sector so far this year.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
5 Momentum Stocks to Buy for April Despite a Disappointing March
by Nalak Das
Five stocks have strong momentum for April. These are: APP, MRVL, DOCS, RDDT, VEEV.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Making Sense of Trade Wars
by John Blank
We discuss trade wars, versus traditional trade policy.
Zacks Industry Outlook Highlights Cencora, Doximity and Pediatrix Medical
by Zacks Equity Research
Cencora, Doximity and Pediatrix Medical are part of the Zacks Industry Outlook article.